Sam Brusco, Associate Editor04.19.22
Bladder and bowel dysfunction treatment products maker Axonics has launched its new Axonics F15 sacral neuromodulation (SNM) system. The long-lived, recharge-free device earned FDA approval in March.
“The Axonics recharge-free system is a welcome advancement for patients suffering from bladder and bowel dysfunction,” Taylor Moore, M.D., a board-certified urologist at Arkansas Urology told the press. “My initial implants of the new device have gone well, with low amplitudes achieved at the time of implant suggesting longevity in the body of around 20 years. Clinical outcomes with the Axonics rechargeable SNM system have exceeded our expectations and we anticipate similar results with the Axonics F15. We are pleased to now offer patients a non-rechargeable option that provides significant longevity in the body, constant current stimulation, and a remote control that is recharge-free and easy for patients to use.”
Axonics F15’s functional life was validated for over 15 years at typical settings and 20 at lower energy settings. It is sized at 10 cubic centimeters, 20% smaller than the market’s other non-rechargeable SNM implant according to the company. A proprietary algorithm recommends ideal stimulation parameters based on intraoperative responses.
“Physician response to the Axonics F15 has been overwhelmingly positive,” said Axonics CEO Raymond W. Cohen. “Our sales team is now armed with a complete portfolio of SNM products that, along with our national DTC campaign, will contribute to Axonics achieving its mission of treating more adults suffering from incontinence. We remain confident that our commitment to innovation, quality, and providing physicians and patients strong support will continue to drive SNM market expansion and advance Axonics on its path to market leadership.”
“The Axonics recharge-free system is a welcome advancement for patients suffering from bladder and bowel dysfunction,” Taylor Moore, M.D., a board-certified urologist at Arkansas Urology told the press. “My initial implants of the new device have gone well, with low amplitudes achieved at the time of implant suggesting longevity in the body of around 20 years. Clinical outcomes with the Axonics rechargeable SNM system have exceeded our expectations and we anticipate similar results with the Axonics F15. We are pleased to now offer patients a non-rechargeable option that provides significant longevity in the body, constant current stimulation, and a remote control that is recharge-free and easy for patients to use.”
Axonics F15’s functional life was validated for over 15 years at typical settings and 20 at lower energy settings. It is sized at 10 cubic centimeters, 20% smaller than the market’s other non-rechargeable SNM implant according to the company. A proprietary algorithm recommends ideal stimulation parameters based on intraoperative responses.
“Physician response to the Axonics F15 has been overwhelmingly positive,” said Axonics CEO Raymond W. Cohen. “Our sales team is now armed with a complete portfolio of SNM products that, along with our national DTC campaign, will contribute to Axonics achieving its mission of treating more adults suffering from incontinence. We remain confident that our commitment to innovation, quality, and providing physicians and patients strong support will continue to drive SNM market expansion and advance Axonics on its path to market leadership.”